España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Eli Lilly
LLY
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$878.31
7.94
0.91%
At close: -
$878.09
-0.22
-0.03%
After Hours: Feb 7, 6:45 PM EDT
Get Report
Comment
The dividend Ex-Date is in 5 days
Q4 2024 Earnings were released on Thu Feb 6th, before the market open
The most recent conference call was at 10:00 AM, 3 days ago
Click to view past webcast
Eli Lilly (LLY) Forecast
News
Earnings
Eli Lilly (LLY) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Eli Lilly (NYSE:LLY) Stock
Eli Lilly Stock (NYSE: LLY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, February 07, 2025
Magnificent Seven Slip, Inflation Fears Grip Consumers, Gold Hits Record Highs: This Week In The Markets
Piero Cingari
Looking Into Eli Lilly's Recent Short Interest
Benzinga Insights
Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
Vandana Singh
Eli Lilly Reports Results From VIVID-2 Open-l...
Benzinga Newsdesk
Thursday, February 06, 2025
A Closer Look at Eli Lilly's Options Market Dynamics
Benzinga Insights
Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?
Piero Cingari
Trump Focused On 10-Year Yield And Not On The Fed, Slower AI Growth Fears Weigh On Arm Stock
The Arora Report
Lilly Exec Says U.S. Prescriptions Of Alzheim...
Benzinga Newsdesk
Lilly Exec Says In Q4 Zepbound Became The Mar...
Benzinga Newsdesk
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
Vandana Singh
CORRECTION: Eli Lilly FY25 Outlook: Adj EPS $...
Benzinga Newsdesk
Eli Lilly Q4 2024 Adj EPS $5.32 Beats $4.94 E...
Benzinga Newsdesk
US Stocks Likely To Open Higher Ahead Of Amazon's Earnings: 'Buy The Dip' Mentality Remains Prevalent, Says Analyst
Rishabh Mishra
Earnings Scheduled For February 6, 2025
Benzinga Insights
Eli Lilly Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Avi Kapoor
Wednesday, February 05, 2025
Eli Lilly Bulls Take Charge Ahead Of Q4 — Can It Reach $1000?
Surbhi Jain
What To Expect When Eli Lilly Reports Q4 Earnings On Thursday?
Vandana Singh
Tuesday, February 04, 2025
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Vandana Singh
Monday, February 03, 2025
Truist Securities Maintains Buy on Eli Lilly,...
Benzinga Newsdesk
Friday, January 31, 2025
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Nabaparna Bhattacharya
Eli Lilly Unusual Options Activity
Benzinga Insights
Thursday, January 30, 2025
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Benzinga Insights
Wednesday, January 29, 2025
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Anthony Noto
Jim Cramer: This Industrial Stock Is 'Absolutely Terrific', First Solar Is 'Very Inexpensive'
Avi Kapoor
Marjorie Taylor Greene Loads Up On Meta, Amazon, Tesla, Nvidia And Other Stocks As Donald Trump's New Equations With Big Tech Leaders Sets Stage For Growth: What Is At Stake? (UPDATED)
Rishabh Mishra
Tuesday, January 28, 2025
Market Whales and Their Recent Bets on LLY Options
Benzinga Insights
Assessing Eli Lilly: Insights From 7 Financial Analysts
Benzinga Insights
Wells Fargo Maintains Overweight on Eli Lilly...
Benzinga Newsdesk
Citigroup Maintains Buy on Eli Lilly, Lowers ...
Benzinga Newsdesk
Wednesday, January 22, 2025
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
Kaustubh Bagalkote
Tuesday, January 21, 2025
Stock Of The Day: Lilly's Strong Support Level Signals Potential Rebound
Mark Putrino
Sunday, January 19, 2025
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Lekha Gupta
Friday, January 17, 2025
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Anthony Noto
How Is The Market Feeling About Eli Lilly?
Benzinga Insights
'Ozempic Is In The Next Round Of Medicare Dru...
Benzinga Newsdesk
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
Vandana Singh
Thursday, January 16, 2025
U.S. FDA Chief Califf Says Current Regulation...
Benzinga Newsdesk
Eli Lilly's Options: A Look at What the Big Money is Thinking
Benzinga Insights
Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Today
Benzinga Insights
Wednesday, January 15, 2025
Eli Lilly Announces The FDA Has Approved Omvo...
Benzinga Newsdesk
Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall
Vandana Singh
Microsoft, Applied Digital, Rigetti Computing, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Benzinga Neuro
Tuesday, January 14, 2025
Stocks Fail To Rise Despite Benign Producer Inflation, 30-Year Treasury Yields Hit 5%, Eli Lilly Tumbles: What's Driving Markets Tuesday? (CORRECTED)
Piero Cingari
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
Vandana Singh
Eli Lily shares are trading lower after the c...
Benzinga Newsdesk
Eli Lilly Expects 2024 Revenue of $45.0B, Abo...
Benzinga Newsdesk
Monday, January 13, 2025
'Lilly Asks Biden Administration to Pause Dru...
Benzinga Newsdesk
'Lilly Sees New Weight-Loss Pill Approval in ...
Benzinga Newsdesk
Eli Lilly Scoops Up Scorpion Therapeutics' Early-Stage Cancer Program For $2.5 Billion
Vandana Singh
Eli Lilly To Acquire Scorpion Therapeutics' N...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch